Cargando…
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
Immunotherapy has become a cornerstone for the treatment of renal cell carcinoma. Nevertheless, some patients are resistant to immune checkpoint inhibitors. The possibility to identify patients who cannot benefit from immunotherapy is a relevant clinical challenge. We analyzed the association betwee...
Autores principales: | Rossi, Ernesto, Boldrini, Luca, Maratta, Maria Grazia, Gatta, Roberto, Votta, Claudio, Tortora, Giampaolo, Schinzari, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012916/ https://www.ncbi.nlm.nih.gov/pubmed/36723981 http://dx.doi.org/10.1080/21645515.2023.2172926 |
Ejemplares similares
-
Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023) -
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023) -
Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023) -
A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
por: DeBenedette, Mark, et al.
Publicado: (2023) -
Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)